GleamWall
中文EN

VIVS VivoSim Labs, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1497253 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-3.6%
TTM net income YoY-417.8%
TTM EPS YoY-768.6%
Revenue 3-yr CAGR-28.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8,897.8%
Net margin-7,605.9%
FCF margin-7,618.5%
EBITDA margin-8,771.9%

Returns

ROE-143.5%
ROA-104.7%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets27.0%
Debt / equity0.00x
Current ratio3.50x
Interest coverage-1,001.00x

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.7%
Payout ratio—
Capex / revenue63.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-09-302027Q12026-06-302026Q4*2026-03-312025Q32025-12-312025Q22025-09-302025Q12025-06-302025Q4*2025-03-312025Q32024-12-31
Income statement
Revenue$51,000$18,000$40,000$26,000$28,000$37,000$51,000$24,000
Cost of revenue$56,000—$0$0$0$0$0$2,000
Gross profit-$5,000—$40,000$26,000$28,000$37,000$51,000$22,000
R&D expense$1.10M$1.13M$1.12M$1.14M$923,000$1.00M$859,000$1.78M
SG&A expense$2.21M$1.65M$2.10M$1.64M$1.74M$1.95M$2.35M$1.71M
Operating income-$3.32M-$2.76M-$3.19M-$2.75M-$2.63M-$2.92M-$3.15M-$3.47M
Interest expense$0$4,000$4,000$4,000$0$4,000$5,000$5,000
Income tax$0$3,000$0$0$2,000$0$0$0
Net income-$475,000-$1.34M-$5.76M-$2.69M-$2.54M-$2.84M$6.85M-$3.45M
EBITDA-$3.28M-$2.72M-$3.14M-$2.70M-$2.58M-$2.85M-$3.09M-$3.40M
EPS (basic)-0.03-0.25—-1.03-0.98-1.14—-2.28
EPS (diluted)-0.03-0.25—-1.03-0.98-1.14—-2.28
Weighted avg. shares (diluted)16.45M5.24M—2.61M2.60M2.50M—1.50M
Balance sheet
Cash & equivalents$8.56M$1.67M$5.02M$4.29M$6.68M$9.05M$11.31M$1.16M
Receivables$56,000$29,000$32,000$33,000$32,000$32,000$30,000$26,000
Inventory$30,000—$0———$0$0
Current assets$9.40M$3.23M$6.63M$6.04M$7.59M$9.68M$12.13M$2.10M
PP&E, net$217,000$189,000$206,000$248,000$300,000$359,000$419,000$479,000
Total assets$9.92M$3.85M$7.39M$6.96M$9.69M$11.98M$14.65M$3.84M
Current liabilities$2.68M$1.89M$2.79M$2.48M$2.45M$2.14M$3.74M$2.94M
Total liabilities$2.68M$6.19M$8.48M$2.52M$2.62M$2.44M$4.16M$3.48M
Shareholders' equity$7.24M-$2.35M-$1.10M$4.44M$7.07M$9.54M$10.49M$364,000
Shares outstanding18.07M3.19M2.89M2.61M2.61M2.60M1.90M17.13M
Cash flow statement
Operating cash flow-$2.48M-$3.21M-$2.24M-$2.27M-$2.38M-$3.94M-$2.04M-$1.80M
Capital expenditure$62,000$23,000$0$0$0$0$0$0
Free cash flow-$2.54M-$3.24M-$2.24M-$2.27M-$2.38M-$3.94M-$2.04M-$1.80M
Investing cash flow$5.95M-$23,000$94,000$0$0$0$9.00M$4,000
Financing cash flow$3.42M-$118,000$2.88M-$118,000$0$1.68M$3.19M-$216,000
Depreciation & amortization$35,000$40,000$43,000$52,000$59,000$61,000$61,000$67,000
Stock-based compensation$235,000$91,000$86,000$67,000$72,000$78,000$91,000$130,000

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.